Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Bactoblis
The First People's Hospital of Lianyungang
Oral Disease
1 trial -
Basic treatment
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
Best medical management
The First People's Hospital of Lianyungang
Stroke, Ischemic
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Brain Glioma
1 trial -
Bifidobacterium
The First People's Hospital of Lianyungang
Depressive Disorder
1 trial -
Bivalirudin
The First People's Hospital of Lianyungang
ST-segment Elevation Myocardial Infarction (STEMI)
1 trial -
Botulinum Toxin Type A Injection [Botox]
The First People's Hospital of Lianyungang
Rosacea
1 trial -
Breast MRI interpretation
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Breztri Aerosphere
The First People's Hospital of Lianyungang
Lung Cancer, Nonsmall Cell
1 trial -
Budesonide/formoterol
The First People's Hospital of Lianyungang
COPD Exacerbation
1 trial -
Buspirone
The First People's Hospital of Lianyungang
Anxiety Disorders
1 trial -
CAR-CD19 T cell
The First People's Hospital of Lianyungang
B Cell Lymphoma
1 trial -
CCTA, CT-MPI, DSA, FFR
The First People's Hospital of Lianyungang
Coronary Microvascular Disease
1 trial -
CD19 CAR-T cells infusion
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
CMOP+Chidamide
The First People's Hospital of Lianyungang
Newly Diagnosed Peripheral T-cell Lymphoma
1 trial -
CT-FFR assessment
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
CT0590 CAR T Cells
The First People's Hospital of Lianyungang
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CT0594CP
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Cadonilimab
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
Canagliflozin
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus With Complication
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Cholangiocarcinoma
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Cefotiam
The First People's Hospital of Lianyungang
Gastric Varices
1 trial -
Celecoxib
The First People's Hospital of Lianyungang
Low Back Pain
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources